British pet pharmaceutical company Royal Hound has initiated a large-scale clinical study in collaboration with the American Kennel Club (AKC) to assess the safety and long-term efficacy of its canine nutritional supplements. This study aims to rigorously evaluate the effectiveness and safety of essential supplement ingredients that contribute to canine nutritional balance and long-term health, with the goal of collecting data that adheres to international standards.

Royal Hound has garnered widespread acclaim in global markets, including Europe, for its development of tailored solutions that align with dogs’ characteristics and life stages. This collaboration with the American Kennel Club (AKC) aims to scientifically validate the safety and efficacy of its products while enhancing global credibility by demonstrating the long-term effects of ingredients customized to each dog’s breed, age, and health condition. This clinical study, conducted in partnership with AKC-affiliated institutions and encompassing all breeds across the United States, seeks to objectively verify the world-class safety and effectiveness of RoyalHound products.

The primary goals of this clinical study are to scientifically demonstrate the efficacy of the supplements in areas such as immune support, digestive health, joint protection, and antioxidant benefits. The study will analyze the impact of long-term intake of essential vitamins, minerals, and antioxidants on health indicators from various angles, measuring physiological changes such as immune responses, inflammation levels, energy levels, and digestive efficiency based on the administration of each ingredient.

AKC’s expert research team is overseeing the design of clinical trials and the collection of data to ensure compliance with international standards in canine supplement research. To enhance accuracy and precision, Royal Hound has implemented state-of-the-art automated data acquisition systems and specialized equipment tailored to each research topic. Data acquisition devices (DAQs) convert various physical signals into digital data, while bio signal measurement devices facilitate real-time monitoring of physiological indicators, including ECG, EEG, and EMG, in dogs. Additionally, signal analysis software provides detailed visualization and analysis of the collected data, supporting the interpretation and quality control of experimental results. Automated measurement systems and robotic arms have also been integrated to ensure consistent data collection, enabling the systematic gathering of reliable data in controlled environments.

A representative from Royal Hound stated, “This joint study with the AKC marks a significant turning point in fostering greater trust in the pet healthcare market. Once recognized as internationally validated data, the results will serve as compelling evidence of long-term safety and efficacy.” The spokesperson also expressed ambitions, stating, “By providing optimal health solutions for dogs through high-quality research, we will further strengthen the RoyalHound brand’s presence in key pet markets such as the U.S., China, and Korea.”

Royal Hound and the AKC plan to conduct interim analyses and updates of the accumulated data every six months, with a comprehensive report scheduled for release in early 2025. The data obtained from this study will serve as foundational material for the development of future products, supporting ongoing research and development efforts in the pet healthcare sector.